Matthew Bernett | Executive Director, Protein Engineering
Xencor, Inc.

Matthew Bernett, Executive Director, Protein Engineering, Xencor, Inc.

Matthew Bernett, Ph.D. has been at Xencor, Inc. for over 19 years, and is currently an Executive Director in the Protein Engineering group where he has been involved in all aspects of the company’s research efforts. Accomplishments include being a co-inventor of tafasitamab (Monjuvi) as well as Xencor’s bispecific platform of T-cell engaging and immune-oncology bispecifics, leading to over ten programs currently in clinical development. He has deep experience in protein and antibody engineering, drug development (from idea to clinic), and internal and external team leadership including multiple collaborations with external partners.

Appearances:



Festival of Biologics Day 2 @ 17:30

XmAb657 and Plamotamab: Advancing CD19 and CD20 Bispecific T-Cell Engagers for Autoimmune Disease Therapy

Targeted B cell depletion offers a promising approach for treating autoimmune diseases. XmAb657 and plamotamab are novel bispecific T-cell engagers (TCEs) designed to target CD19 and CD20 antigens on B cells, respectively. These agents harness the body's immune system to selectively reduce B cell populations involved in autoimmune responses. This presentation will discuss the design, mechanism of action, and current data on XmAb657 and plamotamab. Our findings demonstrate potent and sustained B cell depletion with favorable pharmacokinetics, including extended half-lives. These results highlight the potential of these TCEs to expand therapeutic options for autoimmune conditions.

Matthew Bernett, Executive Director, Protein Engineering, Xencor, Inc.
last published: 21/Mar/25 16:45 GMT

back to speakers